menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

GLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications

GLPRA for CVD risk reduction in obesity and overweight  Clinical implications
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    AHA 2023 Michael Lincoff focusses in this video on the clinical implications of the results of the SELECT trial. What could the results mean for the treatment of patients with obesity and overweight?

  • Educational information

    This video was recorded during the AHA Scientific Sessions 2023 in Philadelphia, PA, USA.

  • Faculty

    Michael Lincoff, MD is an interventional cardiologist and Vice Chairman for Research of the Department of Cardiovascular Medicine at the Cleveland Clinic in Cleveland, OH, USA. He is also the Director of the Cleveland Clinic Coordinating Center for Clinical Research.

  • Disclosures

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    AHA 2023 Michael Lincoff focusses in this video on the clinical implications of the results of the SELECT trial. What could the results mean for the treatment of patients with obesity and overweight?

  • Educational information

    This video was recorded during the AHA Scientific Sessions 2023 in Philadelphia, PA, USA.

  • Faculty

    Michael Lincoff, MD is an interventional cardiologist and Vice Chairman for Research of the Department of Cardiovascular Medicine at the Cleveland Clinic in Cleveland, OH, USA. He is also the Director of the Cleveland Clinic Coordinating Center for Clinical Research.

  • Disclosures

Facebook Comments

Schedule24 May 2024